Professionals Services Insights Community About Offices Careers
Home / Professionals / Robert S. Schwartz, Ph.D.
PDF

Robert S. Schwartz, Ph.D.

Partner
Schwartz Robert
vCard
rschwartz@Venable.com
New York - 1290 Avenue of the Americas
T +1 212.218.2298 F +1 212.218.2200
Robert Schwartz is a patent attorney who focuses on biotechnology and pharmaceutical patent litigation, contested cases before the United States Patent and Trademark Office (USPTO), technical counseling, and patentability and non-infringement opinions. Bob’s primary areas of experience are in biotechnology – particularly protein biochemistry, cell biology, immunology, molecular biology, genomics, proteomics – and the chemical arts. He has worked with transgenic mice, antibodies, fusion proteins, enzyme inhibitors, cell growth factors, receptor antagonists, nucleotide sequencing technology, antiviral drugs, prodrugs, and vaccines.

Prior to becoming an attorney, Bob was an associate professor of medicine at the Albert Einstein College of Medicine, where he was a principal investigator conducting grant-funded biomedical research in hereditary anemias, malaria, and diabetes. He also worked as a staff scientist at Children's Hospital Oakland Research Institute (CHORI).

Related Practices

Experience

Representative Matters

  • Represented Columbia University against Illumina in a patent litigation related to DNA sequencing products
  • Represented Gilead against Teva in an abbreviated new drug application (ANDA) patent litigation related to Atripla® and Truvada® products
  • Represented GlaxoSmithKline against Teva in an ANDA patent litigation related to GlaxoSmithKline’s Avodart® product
  • Represented Bristol-Myers Squibb against Repligen and Zymogenetics in patent litigations related to Bristol-Myers Squibb’s Orencia® product
  • Represented GlaxoSmithKline against Dr. Reddy’s Laboratories, Cobalt Pharmaceuticals, and Spectrum Pharmaceuticals in ANDA patent litigations related to GlaxoSmithKline’s Imitrex® product
  • Represented G.D. Searle and Pharmacia against the University of Rochester in a patent litigation related to G.D. Searle and Pharmacia’s Celebrex® product
  • Represented Regeneron against Genentech in a patent litigation related to Eylea®

Representative Clients

  • Advaxis
  • Alnylam
  • AstraZeneca
  • Bristol-Myers Squibb
  • Columbia University
  • GlaxoSmithKline
  • Regeneron
  • Sanofi

Insights

Recent Thought Leadership

July 07, 2016

180-Day Advance Notice of First Commercial Marketing Is Mandatory For All Biosimilar Applicants
180-Day Advance Notice of First Commercial Marketing Is Mandatory For All Biosimilar Applicants

June 24, 2016

Courts Invalidating Life Sciences Discoveries at Alarming Rate Under Mayo/Alice
Courts Invalidating Life Sciences Discoveries at Alarming Rate Under Mayo/Alice

May 12, 2015

Federal Circuit Halts Market Launch of the First U.S. Biosimilar
Federal Circuit Halts Market Launch of the First U.S. Biosimilar
View More

Events

November 14 - 16, 2018

BIO IPCC's Fall 2018 Conference
BIO IPCC's Fall 2018 Conference

Credentials
+

Education

  • J.D. magna cum laude Pace University School of Law 2003
    • Editor, Pace Law Review
  • Ph.D. summa cum laude University of California at Berkeley
  • B.S. magna cum laude State University of New York at Albany

Bar Admissions

  • New York

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Western District of New York
  • U.S. District Court for the Southern District of New York

Professional Memberships and Activities

  • Authored more than 40 scientific articles and book chapters published in peer-reviewed journals, and numerous articles related to patentability, biologics, and biosimilars
  • Frequent speaker at conferences on biologics and biosimilars

Recognition
+

  • Recognized in Legal 500, Patent Litigation – Full Coverage, 2007, 2014